Yinjia Biosciences will provide Porton Advanced with high-quality core protein raw materials and testing reagent products for quality control and evaluation systems.
N-nitroso dimethylamine (NDMA) is a probable human carcinogen and tts effects on humans rely on observational studies.
The marketing authorisations for three generic drugs signifying advances in cancer treatment will considerably benefit thousands of patients by improving access, ensuring affordability
The new Beyfortus data are consistent with all data accumulated to date and confirm its strong profile
The new company will utilize Teijin's drug discovery research technologies, facilities, equipment and personnel.
The workshop strived to sensitize states and various stakeholder departments regarding their role in the implementation of National Patient Safety Implementation Framework, as well as augment capacity building of health care professionals
The company's consolidated revenues for the quarter grew 36% to Rs. 3,020 crore on the back of robust performance across all its three businesses
Dr. Dietmar Berger, has agreed to take the leadership of the team ad interim
To bring quality cancer treatment closer to patients, India’s leading MedTech brand is joining forces with the unique technology-led platform
The company is in the process of appointing the new Chief Financial Officer shortly and in the interim, Komal Gupta will continue as CFO
Subscribe To Our Newsletter & Stay Updated
